This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
New York-based Bristol-Myers Squibb is a one of the leading global specialty bio-pharmaceutical companies focused on the development of treatments targeting serious diseases. Backed by its blockbuster immune-oncology drug, Opdivo, Bristol-Myers has a strong oncology portfolio, consisting of other drugs like Revlimid, Sprycel, Yervoy and Empliciti. Beyond oncology, the company has important immunology and cardiovascular drugs like Orencia and Eliquis, which diversify its portfolio. Notably, in the cardiovascular space, Eliquis is now the global leading oral anti-coagulant drug. The company continues to experience growth in both the Eliquis brand and the market, while also advancing its Factor XIa inhibitor program..
Disney Whistleblower's Time in the Sun
by Sejuti Banerjea
Former Disney employee Sandra Kuba says company executives have been overstating revenues.
Exelixis (EXEL) Stock Up 15.2% YTD on Strong Cabometyx Sales
by Zacks Equity Research
Exelixis (EXEL) continues to fortify its footing in the kidney cancer market on strong Cabometyx performance.
Why Bristol-Myers Squibb (BMY) is a Top Dividend Stock for Your Portfolio
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Bristol-Myers Squibb (BMY) have what it takes? Let's find out.
4 High Earnings Yield Stocks to Bolster Your Portfolio
by Zacks Equity Research
Earnings yield is quite effective for determining undervalued stocks.
Recession Fears Ebb on Fresh Wave of Stimulus: 5 Top Gainers
by Tirthankar Chakraborty
Fears of recession ebb after White House considers tax cuts for millions of workers, China unveils new interest rate reforms and Germany hints at stimulus measures.
New Strong Buy Stocks for August 20th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Tuesday
Celgene Gets FDA Approval for Inrebic in Bone Marrow Cancer
by Zacks Equity Research
Celgene's (CELG) oncology portfolio gets a boost with the FDA approval of Inrebic for rare bone marrow cancer.
Roche Receives FDA Nod for Rozlytrek in ROS1-positive NSCLC
by Zacks Equity Research
Roche's (RHHBY) lung cancer portfolio gets a boost with the approval of yet another drug, Rozlytrek, for metastatic NSCLC.
Moleculin Completes Enrollment in Early-Stage Cancer Study
by Zacks Equity Research
Moleculin (MBRX) reaches enrollment target in a clinical study evaluating its p-STAT3 inhibitor, WP1220, as a treatment for cutaneous T-cell lymphoma, a form of skin cancer.
Merck's Cancer Immunotherapy Keytruda Continues to Aid Growth
by Zacks Equity Research
Merck's (MRK) Keytruda is rapidly gaining strength as a key contributor to the company's top line. The Keytruda development program is also progressing well.
Should Value Investors Pick Bristol-Myers Squibb (BMY) Stock?
by Zacks Equity Research
Is Bristol-Myers Squibb (BMY) a great pick from the value investor's perspective right now? Read on to know more.
AVEO Pharmaceuticals (AVEO) Q2 Earnings Beat, Revenues Lag
by Zacks Equity Research
AVEO Pharmaceuticals' (AVEO) loss is narrower than expected in the second quarter of 2019. However, revenues fall short of estimates.
Nektar (NKTR) Q2 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
Nektar's (NKTR) reports narrower-than expected loss in the second quarter but stock declines.
Top Research Reports: Bristol-Myers, CME Group, Chubb & More
by Kalyan Nandy
Today's Research Daily features updated research reports on 16 major stocks, including Bristol-Myers (BMY), CME Group (CME) and Chubb (CB).
Celldex (CLDX) Q2 Loss Narrower Than Expected, Revenues Miss
by Zacks Equity Research
Celldex (CLDX) reports mixed second-quarter results. Revenues fall on reduced collaboration and contract revenues.
Mallinckrodt (MNK) Q2 Earnings Beat, Generics Spin-off on Hold
by Zacks Equity Research
Mallinckrodt (MNK) beats on earnings in Q2 but marginally misses on revenues. The company suspends plan to spin-off the generic business for now.
Clovis (CLVS) Q2 Earnings & Sales Lag Estimates, Shares Down
by Zacks Equity Research
Clovis (CLVS) reports dismal second-quarter 2019 results. The company provides lower-than-expected guidance for product sales in 2019.
4 High Earnings Yield Stocks to Strengthen Your Portfolio
by Zacks Equity Research
Earnings yield is very useful for determining undervalued stocks.
Exelixis (EXEL) Q2 Earnings & Sales Beat, Cabometyx Shines
by Zacks Equity Research
Exelixis (EXEL) beats on earnings and sales in the second quarter, as lead drug Cabometyx continues momentum.
Is a Beat in Store for Nektar (NKTR) This Earnings Season?
by Zacks Equity Research
The focus will be on Nektar Therapeutics' (NKTR) pipeline progress and launch plans for NKTR-181 when the company reports second-quarter results.
Biotech Stock Roundup: Celgene, Amgen, Gilead Impress in Q2, Other Pipeline Updates
by Zacks Equity Research
Impressive second-quarter results by most biotech bigwigs are the key highlights of the week. Most companies also increase their annual guidance.
Celgene (CELG) Beats on Q2 Earnings, Raises Revenue Guidance
by Zacks Equity Research
Celgene (CELG) beats on earnings and sales in second-quarter 2019. The company raises full-year revenue guidance on solid Pomalyst and Abraxane performances.
Infinity (INFI) Q2 Loss Wider Than Expected, Sales Miss
by Zacks Equity Research
Infinity (INFI) posts wider-than-expected loss in the second quarter of 2019 and misses sales estimates.
Is Bristol-Myers Squibb (BMY) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Exelixis (EXEL) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Exelixis' (EXEL) second-quarter 2019 results are expected to benefit from increase in Cabometyx sales. Investors will focus on other pipeline updates as well.